← BOSTON SCIENTIFIC CORP

	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Total Revenue	$8.4b	$9.0b	$9.8b	$10.7b	$9.9b	$11.9b	$12.7b	$14.2b	$16.7b	$20.1b
Cost of Revenue	$2.4b	$2.6b	$2.8b	$3.1b	$3.5b	$3.7b	$4.0b	$4.3b	$5.3b	$6.2b
Gross Profit	$6.0b	$6.5b	$7.0b	$7.6b	$6.4b	$8.2b	$8.7b	$9.9b	$11.5b	$13.9b
Operating Expenses	$5.5b	$5.2b	$5.5b	$6.1b	$6.5b	$7.0b	$7.1b	$7.6b	$8.9b	$10.2b
Operating Income (Loss)	$447.0m	$1.3b	$1.5b	$1.5b	($80.0m)	$1.2b	$1.6b	$2.3b	$2.6b	$3.6b
Additional Financial Items
Amortization of Intangible Assets	$545.0m	$565.0m	$599.0m	$699.0m	$789.0m	$741.0m	$803.0m	$828.0m	$856.0m	$897.0m
Foreign Currency Transaction Gain (Loss), before Tax	($13.0m)	—	—	—	—	—	—	—	—	—
Gain (Loss) on Investments	($21.0m)	($92.0m)	$155.0m	($30.0m)	$398.0m	$250.0m	($1.0m)	($59.0m)	($79.0m)	$139.0m
Goodwill, Impairment Loss	$0	—	—	—	$73.0m	$0	$0	$1.0m	($8.0m)	($6.0m)
Income (Loss) from Continuing Operations before Income Taxes, Domestic	($1.0b)	($408.0m)	$35.0m	($1.1b)	($660.0m)	($648.0m)	($1.1b)	($394.0m)	($261.0m)	($311.0m)
Income (loss) before income taxes	$177.0m	$933.0m	$1.4b	$687.0m	($79.0m)	$1.1b	$1.1b	$2.0b	$2.3b	$3.4b
Intangible asset impairment charges	$11.0m	$4.0m	$35.0m	$105.0m	$460.0m	$370.0m	$132.0m	$58.0m	$386.0m	$46.0m
Litigation-related net charges (credits)	$804.0m	$285.0m	$103.0m	$115.0m	$278.0m	$430.0m	$173.0m	($111.0m)	$0	$194.0m
Other, net	($37.0m)	($124.0m)	$156.0m	($358.0m)	$362.0m	$218.0m	($38.0m)	($93.0m)	($16.0m)	$121.0m
Preferred stock dividends	—	—	$0	$0	$33.0m	$55.0m	$55.0m	$23.0m	$0	$0
Restructuring net charges (credits)	$28.0m	$37.0m	$36.0m	$38.0m	$52.0m	$40.0m	$24.0m	$69.0m	$16.0m	$101.0m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$177.0m	$933.0m	$1.4b	$687.0m	($79.0m)	$1.1b	$1.1b	$2.0b	$2.3b	$3.4b
Net Income (Loss) Available to Common Stockholders, Basic	$347.0m	$104.0m	$1.7b	$4.7b	($115.0m)	$985.0m	$642.0m	$1.6b	$1.9b	$2.9b
Net Income (Loss) Attributable to Noncontrolling Interest	$0	—	—	—	$73.0m	$0	$0	$1.0m	($8.0m)	($6.0m)
Net income (loss) attributable to noncontrolling interests	—	—	—	—	—	$0	$0	($1.0m)	($8.0m)	($6.0m)
Earnings Per Share, Basic	$0.26	$0.08	$1.21	$3.38	($0.08)	$0.69	$0.45	$1.08	$1.26	$1.96
Earnings Per Share, Diluted	$0.25	$0.08	$1.19	$3.33	($0.08)	$0.69	$0.45	$1.07	$1.25	$1.94
Weighted Average Number of Shares Outstanding, Basic	1.4b	1.4b	1.4b	1.4b	1.4b	1.4b	1.4b	1.5b	1.5b	1.5b
Weighted Average Number of Shares Outstanding, Diluted	1.4b	1.4b	1.4b	1.4b	1.4b	1.4b	1.4b	1.5b	1.5b	1.5b
Amortization expense	$545.0m	$565.0m	$599.0m	$699.0m	$789.0m	$741.0m	$803.0m	$828.0m	$856.0m	$897.0m
Contingent consideration net expense (benefit)	$29.0m	($80.0m)	($21.0m)	($35.0m)	($100.0m)	($136.0m)	$35.0m	$58.0m	($5.0m)	$18.0m
Cost of products sold (excluding amortization expense)	$2.4b	$2.6b	$2.8b	$3.1b	$3.5b	$3.7b	$4.0b	$4.3b	$5.3b	$6.2b
Current Income Tax Expense (Benefit)	$173.0m	$584.0m	($87.0m)	$275.0m	$87.0m	$178.0m	$451.0m	$320.0m	$526.0m	$505.0m
Interest Expense	$233.0m	$229.0m	$241.0m	$473.0m	$361.0m	$341.0m	$470.0m	$265.0m	$305.0m	$349.0m
Other Nonoperating Income (Expense)	($37.0m)	($124.0m)	$156.0m	($358.0m)	$362.0m	$218.0m	($38.0m)	($93.0m)	($321.0m)	($228.0m)
Research and development expenses	$920.0m	$997.0m	$1.1b	$1.2b	$1.1b	$1.2b	$1.3b	$1.4b	$1.6b	$2.1b
Restructuring and Related Cost, Incurred Cost	$78.0m	$95.0m	—	—	—	—	—	—	—	—
Royalty expense	$79.0m	$68.0m	$70.0m	$65.0m	$45.0m	$49.0m	$47.0m	$46.0m	$33.0m	$46.0m
Selling, General and Administrative Expense	$3.1b	$3.3b	$3.6b	$3.9b	$3.8b	$4.4b	$4.5b	$5.2b	$6.0b	$6.9b
Selling, general and administrative expenses	$3.1b	$3.3b	$3.6b	$3.9b	$3.8b	$4.4b	$4.5b	$5.2b	$6.0b	$6.9b
Income Tax Expense (Benefit)	($170.0m)	$828.0m	($249.0m)	($4.0b)	$2.0m	$36.0m	$443.0m	$393.0m	$436.0m	$493.0m
Other Operating Income (Expense), Net	$447.0m	$1.3b	$1.5b	$1.5b	($362.0m)	($218.0m)	$38.0m	$93.0m	$16.0m	$3.6b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.